In the wake of Biocon’s debut positive opinion for an aflibercept rival to Eylea just over a year ago, two further companies – Sandoz and Samsung Bioepis – have now secured coveted endorsements from the European Medicines Agency for their own versions of the ophthalmic biosimilar. Meanwhile, Teva has received a CHMP nod for another Imnovid generic.

Sandoz and partner Liquidia have welcomed a US court decision which found that interference by United Therapeutics with the launch of their generic treprostinil injection rival to Remodulin caused the pair losses of more than $137m.

At the recent Morgan Stanley Healthcare Conference in New York, Sandoz leaders set out their views on the significance of – and the FDA’s initial implementation of – the US biosimilar interchangeability designation.

After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.